LAG-3/MHCII Blockade Bioassay Technical Manual
Instructions for Use of Product(s)
JA1111, JA1115, JA2111, JA2115
Literature # TM577
The LAG-3/MHCII Blockade Bioassay is a bioluminescent cell-based assay that measures potency and stability of antibodies and other biologics designed to block the interaction of LAG-3 with its ligand, MHCII. LAG-3, also known as CD223, is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells. LAG-3 plays a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of LAG-3 by its best characterized ligand, major histocompatibility complex II (MHCII), inhibits TCR signaling, cytokine production and proliferation of activated T cells. Therapeutic antibodies designed to block the LAG-3/MHCII interaction show promising results in clinical trials for the treatment of a variety of cancers.
This Technical Manual is relevant for Cat.# JA1111, JA1115; JA2111, JA2115 (Korea).
Summary of Changes
The following changes were made to the 4/25 revision of this document:
1. Removed an expired patent statement.
2. Text about the product label was revised and moved to Section 3.
Revised 4/25.